Stonehaven Incubate has announced the appointment of Dr. Fabian Kausche as its new Chairman. Dr. Kausche is a seasoned executive with over 25 years’ experience in the animal and consumer health industries. Most recently, he was SVP, Global Head of R&D for Boehringer Ingelheim Animal Health from 2017 to 2018. Between 2008 and 2016, he…
Stonehaven Incubate is celebrating its first birthday and already has three active on-going collaborations to drive improvements in animal health. “We have evaluated over 33 opportunities in the past 12 months, we’ve actively moved forward on three and we have a number in negotiation, with memorandums of understanding and option agreements underway. We target at…
Stonehaven Incubate and US-based biopharmaceutical company Agile Sciences, Inc. have signed a collaboration agreement for the development of innovative veterinary pharmaceutical therapeutic and prophylactic treatments. Agile’s technology consists of a family of small molecules that uniquely disable bacterial protection mechanisms. When combined with antibiotics, including antibiotics which have been rendered ineffective due to resistance issues,…
A new collaboration between Stonehaven Incubate and anti-microbial protein specialist Lysando aims to develop ground-breaking therapies for companion animal infections. The companies have agreed to conduct proof-of-concept trials for new topical treatments based on Artilysin® anti-microbials, an innovative technology platform developed by Lysando. Once the initial studies have been successfully completed, the partners have agreed…
Stonehaven Incubate has appointed Dr Ellie Virtue as Investment Manager. Dr Virtue is a scientific and commercial professional with experience in start-up human and veterinary biotech companies. She has provided consulting and business services to early-stage human, veterinary and agtech companies where her roles have included a wide range of functions including operations, commercialization, R&D…
Stonehaven Incubate has closed capital raising for its first investment, after securing the backing of a group of global life science and animal health investors. Launched earlier this year as an innovative vehicle for human health companies to expand into the animal health sector, the funding will enable the company to invest directly in a…
Dr Mark Heffernan has been appointed the Chief Executive Officer of Stonehaven Incubate. The company, which officially launches this month at the Human Biotech and Animal Health Summit in Boston, has been formed as a vehicle for human biotechnology companies to expand their innovations into the animal health sector. Prior to joining Stonehaven Incubate, Dr…
Swiss based Stonehaven Incubate was formed in February 2018 and is a dedicated, animal health group committed to creating new companies de novo from disruptive human technology. Stonehaven Incubate works with innovators and builds strategies for new, stand-alone animal health companies. It finds experienced management teams and sources the required capital, leaving no stone unturned in its quest to bring human innovations to animal health.
